HIV – Page 3 – media

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
- Source: Pmlive
- 936
- October 30, 2017
Company Insight HIV Shingrix Tivicay Triumeq vaccine
Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
- Source: Sciencedaily
- 574
- October 13, 2017
AIDS HIV Researches vaccine
J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

A couple of months after posting positive late-stage data for its quadruplet-in-one-pill for quelling HIV, J&J says it’s filed a marketing application with the FDA ahead of a planned marketing campaign.
- Source: Endpts
- 563
- September 27, 2017
FDA Gilead GSK HIV J&J Market Views
GSK opens new aluminium salts facility in Scotland

Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
- Source: news.open-medical
- 637
- August 17, 2017
aluminium salt Company Insight HIV ingredient respiratory vaccine
ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence. The LATTE-2 study assessed long-acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen, branded Edurant), given every four or eight weeks to patients with HIV-1 infection who had already achieved viral suppression with a daily three-drug oral regimen of cabotegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs). Following 96 weeks of maintenance treatment, viral suppression rates for the two-drug regimen dosed every eight weeks (94 percent) or every four weeks (87 percent) were comparable to the rate observed in patients continuing with a three-drug oral regimen (84 percent). In the study, data from which were published in The Lancet and presented at the annual conference ...
- Source: Medicaldevice-network
- 521
- July 27, 2017
Clinical Trials formulation HIV Researches
OraSure’s HIV self-test gets WHO prequalification

US-based point-of-care (POC) diagnostics developer OraSure Technologies has obtained prequalification from the World Health Organisation (WHO) for its OraQuick HIV Self-Test (HIVST).
- Source: Medicaldevice-network-com
- 522
- July 26, 2017
Company Insight HIV Researches WHO

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.